Dominik Mumberg
Overview
Explore the profile of Dominik Mumberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1703
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Graham K, Lienau P, Bader B, Prechtl S, Naujoks J, Lesche R, et al.
Cell Chem Biol
. 2024 Mar;
31(7):1247-1263.e16.
PMID: 38537632
This study describes the identification and target deconvolution of small molecule inhibitors of oncogenic Yes-associated protein (YAP1)/TAZ activity with potent anti-tumor activity in vivo. A high-throughput screen (HTS) of 3.8...
2.
Sugawara T, Nevedomskaya E, Heller S, Bohme A, Lesche R, von Ahsen O, et al.
Mol Oncol
. 2024 Jan;
18(3):726-742.
PMID: 38225213
Prostate cancer is a frequent malignancy in older men and has a very high 5-year survival rate if diagnosed early. The prognosis is much less promising if the tumor has...
3.
Bohnke N, Indrevoll B, Hammer S, Papple A, Kristian A, Briem H, et al.
Eur J Nucl Med Mol Imaging
. 2023 Oct;
51(3):669-680.
PMID: 37882848
Purpose: PSMA (prostate-specific membrane antigen) is highly expressed on prostate cancer (PrCa) cells and extensively used as a homing target for PrCa treatment. Most prominently, PSMA-targeting conjugate PSMA-617, carrying a...
4.
Suominen M, Knuuttila M, Sjoholm B, Wilson T, Alhoniemi E, Mumberg D, et al.
Cancers (Basel)
. 2023 Aug;
15(16).
PMID: 37627143
An increased risk of non-pathological fractures in patients with prostate cancer and bone metastases has been associated with combination treatment with radium-223, abiraterone, and prednisone/prednisolone in the absence of bone-protecting...
5.
Zitzmann-Kolbe S, Kristian A, Zopf D, Kamfenkel C, Politz O, Ellingsen C, et al.
Mol Cancer Ther
. 2023 Jun;
22(9):1073-1086.
PMID: 37365121
Targeted alpha therapies (TAT) are an innovative class of therapies for cancer treatment. The unique mode-of-action of TATs is the induction of deleterious DNA double-strand breaks. Difficult-to-treat cancers, such as...
6.
Suominen M, Knuuttila M, Schatz C, Schlicker A, Vaaraniemi J, Sjoholm B, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768509
Radium-223 dichloride and enzalutamide are indicated for metastatic castration-resistant prostate cancer and their combination is currently being investigated in a large phase 3 clinical trial. Here, we evaluated the antitumor...
7.
Nevedomskaya E, Sugawara T, Baumgart S, Lesche R, Hahne H, Mumberg D, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36611998
Several inhibitors of androgen receptor (AR) function are approved for prostate cancer treatment, and their impact on gene transcription has been described. However, the ensuing effects at the protein level...
8.
Regan J, Schumacher D, Staudte S, Steffen A, Lesche R, Toedling J, et al.
iScience
. 2022 Jun;
25(7):104498.
PMID: 35720265
Recent evidence demonstrates that colon cancer stem cells (CSCs) can generate neurons that synapse with tumor innervating fibers required for tumorigenesis and disease progression. Greater understanding of the mechanisms that...
9.
Bohnke N, Berger M, Griebenow N, Rottmann A, Erkelenz M, Hammer S, et al.
Bioconjug Chem
. 2022 Jun;
33(6):1210-1221.
PMID: 35658441
Inhibition of intracellular nicotinamide phosphoribosyltransferase (NAMPT) represents a new mode of action for cancer-targeting antibody-drug conjugates (ADCs) with activity also in slowly proliferating cells. To extend the repertoire of available...
10.
Sommer A, Berndt S, Lerchen H, Forveille S, Sauvat A, Mumberg D, et al.
Oncoimmunology
. 2022 Feb;
11(1):2037216.
PMID: 35154909
Antibody-drug conjugates (ADCs) are used to target cancer cells by means of antibodies directed to tumor-associated antigens, causing the incorporation of a cytotoxic payload into target cells. Here, we characterized...